Elephas Announces $41.5 Million in Series B Funding
Summary
Oncology drugs remain the largest pharmaceutical therapeutic area, with immunotherapies emerging in the last decade as effective and powerful tools in the fight against cancer. ""Technology that will allow patients to receive the most effective therapy quickly, before time and resources are spent on ineffective options, will change the game for those diagnosed with cancer," ARCH Venture Partners Paul Berns added. This follows the recent appointment by the company of Steven Galson, the former director of the Center for Drug Evaluation and Research at FDA, as independent director.Disruption in healthcare is being accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision making and accelerate drug development. Learn more at npv.vc.Moore Strategic Ventures, LLC is the privately held investment company for Louis M. Bacon, Founder and CEO of Moore Capital Management, LP.Tao Capital Partners is a family office that invests in technology, alternative energy and transportation, healthcare, education, sustainable food & agriculture, consumer, and real estate businesses that have a positive impact.